Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,161,810 papers from all fields of science
Search
Sign In
Create Free Account
Anti-LAG-3 Monoclonal Antibody BMS-986016
Known as:
BMS-986016
, BMS986016
A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract B076: Pan-cancer analysis to identify which cancers may benefit most from LAG-3 blockade
S. Ganesan
,
Anshuman Panda
,
G. Bhanot
Mutational Analysis and Predicting Response to…
2019
Corpus ID: 86581838
Immune checkpoint blockade using antibodies that target programmed-cell-death-1 (PD-1) or its ligand programmed-cell-death-ligand…
Expand
Review
2018
Review
2018
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
A. Neesse
,
C. Bauer
,
+5 authors
T. Gress
Gut
2018
Corpus ID: 52149634
Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The tumour microenvironment (TME) in PDA is…
Expand
Review
2018
Review
2018
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas
Yi Wang
,
Ling Wu
,
C. Tian
,
Yizhuo Zhang
Annals of Hematology
2018
Corpus ID: 12433488
Tumor cells can evade immune surveillance through overexpressing the ligands of checkpoint receptors on tumor cells or adjacent…
Expand
2018
2018
Lag-3 Mediates Acute Rejection & Memory In Mouse Transplantation
J. M. Erfe
2018
Corpus ID: 81245419
Lymphocyte Activation Gene-3 (LAG-3) is a soluble protein and transmembrane protein receptor expressed on lymphocytes such as…
Expand
Highly Cited
2017
Highly Cited
2017
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.
P. Ascierto
,
I. Melero
,
+16 authors
E. Muñoz-Couselo
2017
Corpus ID: 79824525
9520Background: Signaling via LAG-3 and other T-cell inhibitory receptors (eg, PD-1) can lead to T-cell dysfunction and tumor…
Expand
Highly Cited
2017
Highly Cited
2017
LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1…
P. Ascierto
,
P. Bono
,
+15 authors
E. M. Couselo
2017
Corpus ID: 90707080
Highly Cited
2014
Highly Cited
2014
Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
Shihao Chen
,
Li-Fen Lee
,
+12 authors
John C. Lin
Cancer immunology research
2014
Corpus ID: 1975574
Chen, Lee, and colleagues compared the antitumor activity of anti-PD-1 in combination with anti-4-1BB versus with anti-LAG-3 and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE